The STEAP4 target NQO1 mediates colon tumorigenesis
Journal of Cell Science · 2025
DOI: 10.1242/jcs.263402 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cell Science, 2025. Verfasst von Kunlun Yin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, University of New Mexico, Albuquerque, NM 87131, USA. Hauptthemen laut MEDLINE: NAD(P)H Dehydrogenase (Quinone), Carcinogenesis, Colonic Neoplasms, Membrane Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of New Mexico Health Sciences Center, NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Colorectal cancer (CRC) remains a major global health concern, necessitating advancements in therapeutic strategies. Understanding the mechanisms driving CRC is crucial for developing effective treatments. Previous studies, including our own, highlight the role of six-transmembrane epithelial antigen of prostate 4 (STEAP4) in promoting colon tumorigenesis through reactive oxygen species (ROS) generation, making it a promising target. Our research provides compelling evidence that STEAP4 knockout significantly reduces colon tumorigenesis in a genetically engineered mouse model. Suppressing STEAP4 via knockdown techniques effectively attenuated the nuclear factor erythroid 2-related factor 2 (NRF2)–NAD(P)H:quinone oxidoreductase 1 (NQO1) signaling pathway, inducing apoptosis and autophagy, leading to substantial reductions in xenograft tumor growth. In contrast, STEAP4 overexpression amplified ROS production and activated the NRF2–NQO1 pathway in a ferric iron (Fe3+)-dependent manner. Notably, bioactivatable drugs targeting NQO1 were highly effective at eradicating STEAP4-overexpressing colon cancer cells. These findings highlight the potential of targeted therapeutic interventions for CRC, particularly through STEAP4 modulation. In conclusion, our study advances understanding of the role of STEAP4 in colon tumorigenesis, offering promising avenues for novel CRC treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biology, University of New Mexico, Albuquerque, NM 87131, USA.
- Division of Molecular Medicine, Department of Internal Medicine, University of New Mexico, Albuquerque, NM 87131, USA.
- Department of Pathology, University of New Mexico, Albuquerque, NM 87131, USA.
- Division of Gastroenterology, Department of Internal Medicine, University of New Mexico, Albuquerque, NM 87131, USA.
- Center for Inflammation Science and Systems Medicine, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation and Technology, Jupiter, FL 33458, USA.
ORCID-Profile: Xiang Xue
Förderung
- University of New Mexico Health Sciences Center
- NIH HHS
- NCI NIH HHS
- NIEHS NIH HHS
- NIGMS NIH HHS
- University of New Mexico
- American Cancer Society
- NIMHD NIH HHS
Zitieren
APA
Yin, K., Villareal, L., Wu, X., Arcos, M., Lee, J., Martin, D. R., In, J. G., Leslie, K., Zhang, D. D., & Xue, X. (2025). The STEAP4 target NQO1 mediates colon tumorigenesis. Journal of Cell Science. https://doi.org/10.1242/jcs.263402
Vancouver
Yin K, Villareal L, Wu X, Arcos M, Lee J, Martin DR, et al. The STEAP4 target NQO1 mediates colon tumorigenesis. Journal of Cell Science. 2025. doi:10.1242/jcs.263402
BibTeX
@article{Yin2025,
author = {Yin, Kunlun and Villareal, Luke and Wu, Xiangxiang and Arcos, Mariella and Lee, Jordan and Martin, David R and In, Julie G and Leslie, Kimberly and Zhang, Donna D and Xue, Xiang},
title = {The STEAP4 target NQO1 mediates colon tumorigenesis},
journal = {Journal of Cell Science},
year = {2025},
doi = {10.1242/jcs.263402}
}
EUVIMED